Skip header and navigation

Refine By

2254 records – page 1 of 226.

A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.

https://arctichealth.org/en/permalink/ahliterature15782
Source
Allergy. 1997 Aug;52(8):853-9
Publication Type
Article
Date
Aug-1997
Author
O T Olsen
K R Larsen
L. Jacobsan
U G Svendsen
Author Affiliation
Department of Pulmonery Medicine and Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Source
Allergy. 1997 Aug;52(8):853-9
Date
Aug-1997
Language
English
Publication Type
Article
Keywords
Adolescent
Adrenergic beta-Agonists - therapeutic use
Adult
Antigens, Dermatophagoides
Asthma - diagnosis - drug therapy - therapy
Bronchial Provocation Tests
Double-Blind Method
Female
Forced expiratory volume
Glycoproteins - administration & dosage - adverse effects - immunology
Humans
Immunoglobulin E - analysis - blood - immunology
Immunotherapy
Male
Middle Aged
Peak Expiratory Flow Rate
Severity of Illness Index
Skin Tests
Steroids - therapeutic use
Vital Capacity
Abstract
Thirty-one adult patients with asthma caused by house-dust mites (HDM) were included in this placebo-controlled, double-blind study to evaluate the efficacy and safety of specific immunotherapy (SIT) with biologically standardized extracts of HDM. The specific diagnosis was confirmed by skin prick tests, specific IgE, and bronchial provocation tests with HDM allergens. The patients were randomized to receive active treatment with extracts of either Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark) or placebo injections. Twenty-three patients completed the study. After 1 year of treatment, we found a clinically important and significant reduction in both asthma medicine consumption (inhaled steroids 38% and beta 2-agonists 46%) and symptom score (57%) in the actively treated group, but not the placebo group. These findings were confirmed by a significant decrease in skin and bronchial sensitivity to HDM in the active group. Additionally, there was a significant difference in the patients' scores for effect in favor of the actively treated group. Total IgE and specific IgE to HDM showed no significant changes before and after treatment for either group. Spirometric lung-function measurements showed a significant increase in forced expiratory volume in 1 s (FEV1) from 85% before to 89% of predicted values after treatment for the actively treated group. Peak-flow measurements at home showed no significant changes during the study. It is concluded that allergen SIT is an effective treatment in adult patients suffering from asthma due to HDM.
PubMed ID
9284985 View in PubMed
Less detail

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

https://arctichealth.org/en/permalink/ahliterature264224
Source
Lancet. 2015 Jun 6;385(9984):2255-63
Publication Type
Article
Date
Jun-6-2015
Author
Tiia Ngandu
Jenni Lehtisalo
Alina Solomon
Esko Levälahti
Satu Ahtiluoto
Riitta Antikainen
Lars Bäckman
Tuomo Hänninen
Antti Jula
Tiina Laatikainen
Jaana Lindström
Francesca Mangialasche
Teemu Paajanen
Satu Pajala
Markku Peltonen
Rainer Rauramaa
Anna Stigsdotter-Neely
Timo Strandberg
Jaakko Tuomilehto
Hilkka Soininen
Miia Kivipelto
Source
Lancet. 2015 Jun 6;385(9984):2255-63
Date
Jun-6-2015
Language
English
Publication Type
Article
Keywords
Aged
Cognition Disorders - epidemiology - prevention & control
Diet
Double-Blind Method
Exercise
Exercise Therapy
Humans
Male
Middle Aged
Neuropsychological Tests
Risk assessment
Vascular Diseases - epidemiology - prevention & control
Abstract
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a proof-of-concept randomised controlled trial, we aimed to assess a multidomain approach to prevent cognitive decline in at-risk elderly people from the general population.
In a double-blind randomised controlled trial we enrolled individuals aged 60-77 years recruited from previous national surveys. Inclusion criteria were CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least 6 points and cognition at mean level or slightly lower than expected for age. We randomly assigned participants in a 1:1 ratio to a 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring), or a control group (general health advice). Computer-generated allocation was done in blocks of four (two individuals randomly allocated to each group) at each site. Group allocation was not actively disclosed to participants and outcome assessors were masked to group allocation. The primary outcome was change in cognition as measured through comprehensive neuropsychological test battery (NTB) Z score. Analysis was by modified intention to treat (all participants with at least one post-baseline observation). This trial is registered at ClinicalTrials.gov, number NCT01041989.
Between Sept 7, 2009, and Nov 24, 2011, we screened 2654 individuals and randomly assigned 1260 to the intervention group (n=631) or control group (n=629). 591 (94%) participants in the intervention group and 599 (95%) in the control group had at least one post-baseline assessment and were included in the modified intention-to-treat analysis. Estimated mean change in NTB total Z score at 2 years was 0·20 (SE 0·02, SD 0·51) in the intervention group and 0·16 (0·01, 0·51) in the control group. Between-group difference in the change of NTB total score per year was 0·022 (95% CI 0·002-0·042, p=0·030). 153 (12%) individuals dropped out overall. Adverse events occurred in 46 (7%) participants in the intervention group compared with six (1%) participants in the control group; the most common adverse event was musculoskeletal pain (32 [5%] individuals for intervention vs no individuals for control).
Findings from this large, long-term, randomised controlled trial suggest that a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population.
Academy of Finland, La Carita Foundation, Alzheimer Association, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture, Salama bint Hamdan Al Nahyan Foundation, Axa Research Fund, EVO funding for University Hospitals of Kuopio, Oulu, and Turku and for Seinäjoki Central Hospital and Oulu City Hospital, Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and af Jochnick Foundation.
Notes
Comment In: Nat Rev Neurol. 2015 May;11(5):24825799934
PubMed ID
25771249 View in PubMed
Less detail

2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.

https://arctichealth.org/en/permalink/ahliterature120892
Source
J Am Coll Cardiol. 2012 Sep 25;60(13):1140-7
Publication Type
Article
Date
Sep-25-2012
Author
Lisette Okkels Jensen
Per Thayssen
Evald Høj Christiansen
Hans Henrik Tilsted
Michael Maeng
Knud Nørregaard Hansen
Anne Kaltoft
Henrik Steen Hansen
Hans Erik Bøtker
Lars Romer Krusell
Jan Ravkilde
Morten Madsen
Leif Thuesen
Jens Flensted Lassen
Author Affiliation
Department of Cardiology, Odense University Hospital, Odense, Denmark. okkels@dadlnet.dk
Source
J Am Coll Cardiol. 2012 Sep 25;60(13):1140-7
Date
Sep-25-2012
Language
English
Publication Type
Article
Keywords
Aged
Angioplasty, Balloon, Coronary
Coronary Artery Disease - mortality - therapy
Death
Denmark
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Immunosuppressive Agents - therapeutic use
Male
Middle Aged
Myocardial Infarction - etiology
Myocardial Revascularization - statistics & numerical data
Single-Blind Method
Sirolimus - adverse effects - analogs & derivatives - therapeutic use
Thrombosis - etiology
Treatment Outcome
Abstract
There are limited head-to-head randomized data on patient-related versus stent-related outcomes for everolimus-eluting stents (EES) and sirolimus-eluting stents (SES).
In the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) trial, comparing the EES with the SES in patients with coronary artery disease, the EES was noninferior to the SES at 9 months.
The primary endpoint was a composite: cardiac death, myocardial infarction (MI), definite stent thrombosis, or target vessel revascularization. Safety and efficacy outcomes at 2 years were further assessed with specific focus on patient-related composite (all death, all MI, or any revascularization) and stent-related composite outcomes (cardiac death, target vessel MI, or symptom-driven target lesion revascularization). A total of 1,390 patients were assigned to receive the EES, and 1,384 patients were assigned to receive the SES.
At 2 years, the composite primary endpoint occurred in 8.3% in the EES group and in 8.7% in the SES group (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.73 to 1.22). The patient-related outcome: 15.0% in the EES group versus 15.6% in the SES group, (HR: 0.95, 95% CI: 0.78 to 1.15), and the stent-related outcome: 5.2% in the EES group versus 5.3% in the SES group (HR: 0.97, 95% CI: 0.70 to 1.35) did not differ between groups. Rate of definite stent thrombosis was lower in the EES group (0.2% vs. 0.9%, (HR: 0.23, 95% CI: 0.07 to 0.80).
At 2-year follow-up, the EES was found to be noninferior to the SES with regard to both patient-related and stent-related clinical outcomes.
PubMed ID
22958957 View in PubMed
Less detail

A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group.

https://arctichealth.org/en/permalink/ahliterature229565
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Publication Type
Article
Date
Mar-1990
Author
A S Rebuck
S. Kesten
L P Boulet
A. Cartier
D. Cockcroft
J. Gruber
F. Laberge
E. Lee-Chuy
M. Keshmiri
G F MacDonald
Author Affiliation
Edmonton General Hospital, Canada.
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects - therapeutic use
Asthma - drug therapy - physiopathology
Canada
Chronic Disease
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Nedocromil
Peak Expiratory Flow Rate - drug effects - physiology
Quinolones - adverse effects - therapeutic use
Randomized Controlled Trials as Topic
Time Factors
Abstract
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative, formulated in a metered-dose inhaler. Because nedocromil sodium has in vitro and in vivo anti-inflammatory properties, it was evaluated in a group of steroid-dependent patients with asthma to observe how well it might be tolerated and for evidence of any beneficial effects. In a double-blind, group-comparative study, 127 patients received nedocromil sodium and 61 received placebo, administered as two puffs of 2 mg, four times per day, for 12 weeks. Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. Two patients of each group withdrew because of worsening asthma. Despite selecting patients whose asthma was stable, when they were receiving established therapeutic regimens that included steroids and bronchodilators, it was found that diary-card symptom scores, morning and evening peak expiratory flow rate values, and inhaled beta-agonist usage all demonstrated slight but significant benefit with addition of nedocromil sodium. It is concluded that the inhaled, anti-inflammatory agent, nedocromil sodium, may be added to asthma-treatment regimens with the reasonable expectation of further modest symptomatic benefit.
PubMed ID
2155958 View in PubMed
Less detail

3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

https://arctichealth.org/en/permalink/ahliterature10861
Source
Lancet. 1998 Apr 18;351(9110):1180-1
Publication Type
Article
Date
Apr-18-1998

5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.

https://arctichealth.org/en/permalink/ahliterature234423
Source
Dig Dis Sci. 1987 Dec;32(12 Suppl):64S-66S
Publication Type
Article
Date
Dec-1987
Author
L R Sutherland
F. Martin
Author Affiliation
Department of Gastroenterology, University of Calgary, Canada.
Source
Dig Dis Sci. 1987 Dec;32(12 Suppl):64S-66S
Date
Dec-1987
Language
English
Publication Type
Article
Keywords
Adult
Aminosalicylic Acids - administration & dosage - therapeutic use
Canada
Clinical Trials as Topic
Colitis, Ulcerative - drug therapy
Double-Blind Method
Enema
Female
Humans
Male
Mesalamine
Proctitis - drug therapy
Random Allocation
Time Factors
Abstract
The efficacy and safety of 4 g 5-aminosalicylic acid (5-ASA) enemas were assessed in 59 patients with ulcerative colitis involving up to 50 cm of their distal colon. Twenty-nine patients received 5-ASA and 30 received a placebo. There were 12 dropouts (five in the active and seven in the placebo group) during the study because of insufficient efficacy. After six weeks of therapy, 63% of the patients receiving the 5-ASA were considered to be "much improved" by the study physician compared to 20% patients on placebo (P less than 0.0001). A disease activity index (DAI), based upon patient symptoms and sigmoidoscopic appearance, was used to assess efficacy. Mean DAI declined 75% for patients on 5-ASA enemas and 32% for patients on placebo (P less than 0.05). The 5-ASA enemas are well tolerated and are of benefit in the treatment of ulcerative colitis confined to the distal colon.
PubMed ID
3319459 View in PubMed
Less detail

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

https://arctichealth.org/en/permalink/ahliterature212248
Source
Acta Ophthalmol Scand. 1996 Apr;74(2):140-4
Publication Type
Article
Date
Apr-1996
Author
B. Friström
Author Affiliation
Department of Ophthalmology, University of Linköping, Sweden.
Source
Acta Ophthalmol Scand. 1996 Apr;74(2):140-4
Date
Apr-1996
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - administration & dosage - adverse effects - therapeutic use
Adult
Aged
Aged, 80 and over
Double-Blind Method
Female
Follow-Up Studies
Glaucoma, Open-Angle - drug therapy - physiopathology
Humans
Intraocular Pressure - drug effects
Male
Middle Aged
Ocular Hypertension - drug therapy - physiopathology
Ophthalmic Solutions
Prostaglandins F, Synthetic - administration & dosage - adverse effects - therapeutic use
Safety
Scandinavia
Timolol - administration & dosage - adverse effects - therapeutic use
Abstract
The intraocular pressure reducing effect and side-effects of latanoprost, a phenyl-substituted prostaglandin analogue, were compared with those of timolol, in a group of 31 glaucomatous or ocular hypertensive patients, divided into three subgroups. The study was randomized and double masked. At the end of 6 month's treatment with latanoprost 0.005% once daily, either as a morning dose or as an evening dose, there was a reduction in intraocular pressure of 33% (p
PubMed ID
8739678 View in PubMed
Less detail

A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine.

https://arctichealth.org/en/permalink/ahliterature119944
Source
J Clin Psychiatry. 2012 Sep;73(9):1234-42
Publication Type
Article
Date
Sep-2012
Author
Klaus Martiny
Else Refsgaard
Vibeke Lund
Marianne Lunde
Lene Sørensen
Britta Thougaard
Lone Lindberg
Per Bech
Author Affiliation
Psykiatrisk Center København, Rigshospitalet, Afsnit 6202, Blegdamsvej 9, 2100 København ø, Denmark. klaus.martiny@regionh.dk
Source
J Clin Psychiatry. 2012 Sep;73(9):1234-42
Date
Sep-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antidepressive Agents - administration & dosage
Combined Modality Therapy
Denmark
Depressive Disorder, Major - drug therapy - therapy
Exercise
Female
Humans
Logistic Models
Male
Middle Aged
Phototherapy
Prospective Studies
Seasons
Single-Blind Method
Sleep Phase Chronotherapy
Thiophenes - administration & dosage
Abstract
The onset of action of antidepressants often takes 4 to 6 weeks. The antidepressant effect of wake therapy (sleep deprivation) comes within hours but carries a risk of relapse. The objective of this study was to investigate whether a new chronotherapeutic intervention combining wake therapy with bright light therapy and sleep time stabilization could induce a rapid and sustained augmentation of response and remission in major depressive disorder.
75 adult patients with DSM-IV major depressive disorder, recruited from psychiatric wards, psychiatric specialist practices, or general medical practices between September 2005 and August 2008, were randomly assigned to a 9-week chronotherapeutic intervention using wake therapy, bright light therapy, and sleep time stabilization (n = 37) or a 9-week intervention using daily exercise (n = 38). Patients were evaluated at a psychiatric research unit. The study period had a 1-week run-in phase in which all patients began treatment with duloxetine. This phase was followed by a 1-week intervention phase in which patients in the wake therapy group did 3 wake therapies in combination with daily morning light therapy and sleep time stabilization and patients in the exercise group began daily exercise. This phase was followed by a 7-week continuation phase with daily light therapy and sleep time stabilization or daily exercise. The 17-item Hamilton Depression Rating Scale was the primary outcome measure, and the assessors were blinded to patients' treatment allocation.
Both groups responded well to treatment. Patients in the wake therapy group did, however, have immediate and clinically significantly better response and remission compared to the exercise group. Thus, immediately after the intervention phase (week 2), response was obtained in 41.4% of wake therapy patients versus 12.8% of exercise patients (odds ratio [OR] = 4.8; 95% CI, 1.7-13.4; P = .003), and remission was obtained in 23.9% of wake therapy patients versus 5.4% of exercise patients (OR = 5.5; 95% CI, 1.7-17.8; P = .004). These superior response and remission rates obtained by the wake therapy patients were sustained for the whole study period. At week 9, response was obtained in 71.4% of wake therapy patients versus 47.3% of exercise patients (OR = 2.8; 95% CI, 1.1-7.3; P = .04), and remission was obtained in 45.6% of wake therapy patients and 23.1% of exercise patients (OR = 2.8; 95% CI, 1.1-7.3, P = .04). All treatment elements were well tolerated.
Patients treated with wake therapy in combination with bright light therapy and sleep time stabilization had an augmented and sustained antidepressant response and remission compared to patients treated with exercise, who also had a clinically relevant antidepressant response.
ClinicalTrials.gov identifier: NCT00149110.
PubMed ID
23059149 View in PubMed
Less detail

A 15-month evaluation of the effects of repeated subgingival minocycline in chronic adult periodontitis.

https://arctichealth.org/en/permalink/ahliterature201582
Source
J Periodontol. 1999 Jun;70(6):657-67
Publication Type
Article
Date
Jun-1999
Author
D. van Steenberghe
B. Rosling
P O Söder
R G Landry
U. van der Velden
M F Timmerman
E F McCarthy
G. Vandenhoven
C. Wouters
M. Wilson
J. Matthews
H N Newman
Author Affiliation
Catholic University, Leuven, Belgium.
Source
J Periodontol. 1999 Jun;70(6):657-67
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Adult
Aggregatibacter actinomycetemcomitans - drug effects
Analysis of Variance
Anti-Bacterial Agents - administration & dosage
Campylobacter - drug effects
Canada
Chronic Disease
Colony Count, Microbial
Dental Plaque Index
Dental Scaling
Double-Blind Method
Eikenella corrodens - drug effects
Europe
Female
Fusobacterium nucleatum - drug effects
Humans
Longitudinal Studies
Male
Middle Aged
Minocycline - administration & dosage
Ointments
Periodontal Index
Periodontal Pocket - drug therapy - microbiology
Periodontitis - drug therapy - microbiology
Porphyromonas gingivalis - drug effects
Prevotella intermedia - drug effects
Statistics, nonparametric
Treatment Outcome
Treponema - drug effects
Abstract
A double-blind, randomized, parallel, comparative study was designed to evaluate the long-term safety and efficacy of subgingivally administered minocycline ointment versus a vehicle control.
One hundred four patients (104) with moderate to severe adult periodontitis (34 to 64 years of age; mean 46 years) were enrolled in the study. Following scaling and root planing, patients were randomized to receive either 2% minocycline ointment or a matched vehicle control. Study medication was administered directly into the periodontal pocket with a specially designed, graduated, disposable applicator at baseline; week 2; and at months 1, 3, 6, 9, and 12. Scaling and root planing was repeated at months 6 and 12. Standard clinical variables (including probing depth and attachment level) were evaluated at baseline and at months 1, 3, 6, 9, 12, and 15. Microbiological sampling using DNA probes was done at baseline; at week 2; and at months 1, 3, 6, 9, 12, and 15.
Both treatment groups showed significant and clinically relevant reductions in the numbers of each of the 7 microorganisms measured during the entire 15-month study period. When differences were detected, sites treated with minocycline ointment always produced statistically significantly greater reductions than sites which received the vehicle control. For initial pockets > or =5 mm, a mean reduction in probing depth of 1.9 mm was seen in the test sites, versus 1.2 mm in the control sites. Sites with a baseline probing depth > or =7 mm and bleeding index >2 showed an average of 2.5 mm reduction with minocycline versus 1.5 mm with the vehicle. Gains in attachment (0.9 mm and 1.1 mm) were observed in minocycline-treated sites, with baseline probing depth > or =5 mm and > or =7 mm, respectively, compared with 0.5 mm and 0.7 mm gain at control sites. Subgingival administration of minocycline ointment was well tolerated.
Overall, the results demonstrate that repeated subgingival administration of minocycline ointment in the treatment of adult periodontitis is safe and leads to significant adjunctive improvement after subgingival instrumentation in both clinical and microbiologic variables over a 15-month period.
PubMed ID
10397521 View in PubMed
Less detail

2254 records – page 1 of 226.